| Literature DB >> 30810672 |
Wuhua Jiang1,2,3, Bo Shen1,2,3, Yimei Wang1,2,3, Jiarui Xu1,2,3, Zhe Luo4, Xiaoqiang Ding1,2,3, Jie Teng1,2,3.
Abstract
OBJECTIVE: To discover potentially modifiable perioperative predictors for renal replacement therapy (RRT) in patients with cardiac surgery-associated acute kidney injury (CSA-AKI).Entities:
Mesh:
Year: 2019 PMID: 30810672 PMCID: PMC6385827 DOI: 10.21470/1678-9741-2018-0206
Source DB: PubMed Journal: Braz J Cardiovasc Surg ISSN: 0102-7638
Fig. 1Flow diagram outlining the inclusion and exclusion criteria and study design. AKI=acute kidney injury; CABG=coronary artery bypass grafting; RRT=renal replacement therapy
Patients' characteristics and perioperative parameters of the AKI-RRT and non-AKI RRT groups in the entire and matched samples.
| Entire cohort | Matched cohort | |||||
|---|---|---|---|---|---|---|
| Non-AKI-RRT (N=1695) | AKI-RRT (N=78) | Non-AKI-RRT (N=78) | AKI-RRT (N=78) | |||
| Male, n (%) | 1104 (65.1) | 52 (66.7) | 0.809 | 59 (75.6) | 52 (66.7) | 0.216 |
| Age, median (IQR), years | 61 (54,67) | 62 (54,69) | 0.217 | 65 (59,70) | 62 (54,69) | 0.05 |
| Serum creatinine, median (IQR), mg/dl | 0.96 (0.8,1.1) | 1.0 (0.8,1.3) | 0.152 | 0.9 (0.8,1.2) | 1.0 (0.8,1.3) | 0.565 |
| eGFR, mean (SD), ml/min/1.73 m2 | 83.7 (22.8) | 76.5 (26.9) | 0.017 | 77.7 (25.3) | 76.5 (26.9) | 0.774 |
| Hypertension, n (%) | 666 (32.3) | 38 (48.7) | 0.096 | 47 (60.3) | 38 (48.7) | 0.148 |
| DM, n (%) | 241 (14.2) | 19 (24.4) | 0.013 | 21 (26.9) | 19 (24.4) | 0.714 |
| NYHA classification >2, n (%) | 1128 (66.6) | 54 (69.2) | 0.057 | 45 (57.7) | 54 (69.2) | 0.135 |
| Interval between CM exposure and surgery <3 days, n (%) | 52 (3.1) | 26 (33.3) | 14 (47.9) | 26 (33.3) | ||
| Hemoglobin, mean (SD), g/dL | 13.19 (16.7) | 12.89 (19.4) | 0.243 | 12.95 (21.6) | 12.89 (19.4) | 0.675 |
| Albumin, mean (SD), g/L | 39.7 (3.4) | 38.5 (3.6) | 0.688 | 39.7 (3.3) | 38.5 (3.6) | 0.481 |
| Valve, n (%) | 1132 (66.8) | 49 (62.8) | 0.468 | 30 (38.5) | 49 (62.8) | 0.002 |
| CABG, n (%) | 417 (24.6) | 11 (14.1) | 0.034 | 31 (39.7) | 11 (14.1) | <0.001 |
| Valve & CABG, n (%) | 146 (8.6) | 18 (23.1) | <0.001 | 17 (21.8) | 18 (23.1) | 0.848 |
| CPB time, mean (SD), min | 107.7 (38.6) | 138.6 (52.7) | <0.001 | 111.7 (45.4) | 138.6 (52.7) | 0.006 |
| CVP, median (IQR), mmHg | 8 (6,10) | 9 (8,11) | <0.001 | 8 (7,10) | 9 (8,11) | <0.001 |
| 1.1 (1.6) | 5.1 (4.4) | <0.001 | 0.8 (1.6) | 5.1 (4.4) | <0.001 | |
| 605 (35.7) | 13 (16.7) | <0.001 | 20 (25.6) | 13 (16.7) | <0.001 | |
| In-hospital mortality, n (%) | 22 (1.3) | 22 (28.2) | <0.001 | 2 (2.6) | 22 (28.2) | <0.001 |
| Length of hospital stay, median (IQR), days | 13(11,19) | 23 (11,47) | <0.001 | 15 (11,19) | 23 (11,47) | 0.008 |
| In-hospital expense, median (IQR), USD | 18522 (15347,22649) | 34712 (23354,45716) | <0.001 | 14672 (12498,19320) | 34712 (23354,45716) | <0.001 |
AKI=acute kidney injury; CABG=coronary artery bypass grafting; CM=contrast media; CPB=cardiopulmonary bypass; CVP=central venous pressure by intensive care unit admittance; DM=diabetes mellitus; eGFR=estimated glomerular filtration rate, calculated by Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formulae; IQR=interquartile range; NYHA=New York Heart Association; RRT=renal replacement therapy; SD=standard deviation; USD=United States Dollar The values are expressed as median (IQR), mean (SD), or number (%).
P-values are the results of unpaired t-test or Mann-Whitney U test for continuous variables, and χ2 test or Fisher's exact test for categorical variables.
The amount of erythrocyte transfusion refers to the amount of transfusion during both intraoperative and postoperative days of surgery.
The complete recovery of renal function is defined as a return of creatinine to no higher than baseline and no dialysis.
Fig. 2The logistic regression's goodness of fit in the propensity score-match model. χ2=7.43, P=0.386
Multivariate analysis of risk factors for the development of acute kidney injury in the matched sample.
| Covariate | β-coefficient | Odds ratio | 95%CI | |
|---|---|---|---|---|
| Interval between preoperative contrast media exposure <3 days | 1.076 | 2.932 | 0.951-9.039 | 0.048 |
| ICU admission CVP >10 mmHg (per mmHg increase) | 0.498 | 1.646 | 1.156-2.344 | 0.006 |
| Erythrocyte transfusions (per unit increase) | 0.555 | 1.742 | 1.358-2.234 | <0.001 |
CI=confidence interval; CVP=central venous pressure; ICU=intensive care unit; LCOS=low cardiac output syndrome
The amount of erythrocyte transfusion refers to the amount of transfusion during both intraoperative and postoperative days of surgery.
Fig. 3Discrimination of the logistic regression model for the risk of acute kidney injury renal replacement therapy (AKI-RRT) in the matched cohort.
Fig. 4The calibration of the logistic regression model for predicting cardiac surgery-associated acute kidney injury (CSA-AKI) in the matched cohort.
| Abbreviations, acronyms & symbols | ||||
|---|---|---|---|---|
| AKI | = Acute kidney injury | eGFR | = Estimated glomerular filtration rate | |
| AUC | = Area under the curve | GEDVI | = Global end-diastolic volume index | |
| CABG | = Coronary artery bypass grafting | ICU | = Intensive care unit | |
| CI | = Confidence interval | IQR | = Interquartile range | |
| CIN | = Contrast-induced nephropathy | KIDGO | = Kidney Disease: Improving Global Outcomes | |
| CKD | = Chronic kidney disease | LCOS | = Low cardiac output syndrome | |
| CKD-EPI | = Chronic Kidney Disease Epidemiology Collaboration | NYHA | = New York Heart Association | |
| CM | = Contrast media | OR | = Odds ratio | |
| CPB | = Cardiopulmonary bypass | RRT | = Renal replacement therapy | |
| CSA-AKI | = Cardiac surgery-associated acute kidney injury | SCr | = Serum creatinine | |
| CVP | = Central venous pressure | SD | = Standard deviation | |
| DM | = Diabetes mellitus | USD | = United States Dollar | |
| Authors' roles & responsibilities | |
|---|---|
| WJ | Analyzed the data, interpreted the results and writing; final approval of the version to be published |
| BS | Analyzed the data; interpreted the results and writing; final approval of the version to be published |
| YW | Participated in data collection and maintenance; final approval of the version to be published |
| JX | Analyzed the data; final approval of the version to be published |
| ZL | Participated in reviewing the manuscript; final approval of the version to be published |
| XD | Designed and directed the study; final approval of the version to be published |
| JT | Designed and directed the study; final approval of the version to be published |